Document:

Exhibit
10.4

 

SECURITIES
PURCHASE AGREEMENT

 

SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of January 9, 2020, by and among Wize Pharma, Inc., a Delaware
corporation, with headquarters located at 24 Hanagar Street, POB 6653, Hod Hasharon 4527708, Israel (the “Company”),
and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively,
the “Buyers”).

 

WHEREAS:

 

A.
The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the
“SEC”) under the 1933 Act.

 

B.
The Company has authorized a new series of convertible preferred stock of the Company designated as Series
B Non-Voting Redeemable Preferred Stock, the terms of which are set forth in the certificate of designation for such series of
preferred stock (the “Certificate of Designations”) in the form attached hereto as Exhibit A (the “Preferred
Shares”).

 

C.
Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, that aggregate
number of Preferred Shares set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers (which aggregate
number for all Buyers shall be 7,500).

 

D.
The aggregate purchase price for the Preferred Shares shall be $7,500,000 (the “Aggregate Purchase Price”).

 

E.
Contemporaneously with the execution and delivery of this Agreement, (i) the Company and Bonus BioGroup Ltd., a company organized
under the laws of the state of Israel (“Bonus”), are executing and delivering the Share Purchase Agreement
(as may be amended from time to time, the “Bonus Purchase Agreement”), (ii) the Company and Bonus are executing
and delivering the Exchange Agreement (as may be amended from time to time, the “Bonus Exchange Agreement”),
and (iii) as contemplated by the Bonus Purchase Agreement, Bonus, the Company, and IBI Trust Management (the “Bonus Escrow
Agent”) are executing and delivering the Escrow Agreement (the “Bonus Escrow Agreement” and, together
with the Bonus Purchase Agreement and Bonus Exchange Agreement, the “Bonus Agreements”), pursuant to which
the Company has agreed to purchase the Bonus Shares (as defined in the Bonus Purchase Agreement) in exchange for the consideration
set forth in the Bonus Agreements.

 

     

     

    

 

NOW,
THEREFORE, the Company and each Buyer hereby agree as follows:

 

1.
PURCHASE AND SALE OF PREFERRED SHARES.

 

(a)
Purchase of Preferred Shares. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below,
the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, shall purchase from the Company on
the Closing Date (as defined below), the number of Preferred Shares as is set forth opposite such Buyer’s name in column
(3) on the Schedule of Buyers (the “Closing”).

 

(b)
Closing. The date and time of the Closing (the “Closing Date”) shall be 10:00 a.m., Israel time, on
the same day immediately following satisfaction (or waiver) of the conditions to the Closing set forth in Sections 6 and 7 below,
at the offices of the Company (or such other date, time and location as is mutually agreed to by the Company and the holders of
at least a majority of the Preferred Shares issuable hereunder (the “Required Holders”)). The Closing may also
be undertaken remotely by electronic transfer of Closing documentation.

 

(c)
Purchase Price. The aggregate purchase price for the Preferred Shares to be purchased by each Buyer at the Closing shall
be the amount set forth opposite each Buyer’s name in column (4) of the Schedule of Buyers (the “Purchase Price”).
Each Buyer shall pay $1,000 for each Preferred Share.

 

(d)
Form of Payment. (i) On the date hereof (or such other time agreed in writing by the Company), each Buyer will have paid
its Purchase Price for the Preferred Shares to be issued and sold to such Buyer at the Closing to the escrow account (the “Escrow
Account”) established by the Company for such purposes under the escrow agreement (the “Escrow Agreement”)
to be entered into among the Company, IBI Trust Management, as escrow agent (the “Escrow Agent”), and the Buyers,
by wire transfer of immediately available funds in accordance with the Company’s written wire instructions, which funds
shall be released to the Company at or immediately prior to the Closing; and (ii) at the Closing, the Company shall deliver
to each Buyer one or more stock certificates, evidencing the number of Preferred Shares such Buyer is purchasing as is set forth
opposite such Buyer’s name in column (3) of the Schedule of Buyers, duly executed on behalf of the
Company and registered in the name of such Buyer or its designee or shall register such Preferred Shares in book entry form with
the Company’s books in such Buyer’s name.

 

(e)
Acceptance of Subscription. Each Buyer understands and agrees that the Company shall have no obligation hereunder
until the Company shall execute and deliver to the Buyer an executed copy of this Agreement.

 

2.
BUYER’S REPRESENTATIONS AND WARRANTIES. Each Buyer, severally and not jointly, represents and warrants with respect
to only itself that, as of the date hereof and as of the Closing Date:

 

(a)
No Public Sale or Distribution. Such Buyer is (i) acquiring the Preferred Shares for its own account and not with a view
towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted
under the 1933 Act; provided, however, that by making the representations herein, such Buyer does not agree to hold
the Preferred Shares for any minimum or other specific term and reserves the right to dispose of the Preferred Shares at any time
in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. Such Buyer is acquiring the Preferred
Shares hereunder in the ordinary course of its business. Such Buyer does not presently have any agreement or understanding, directly
or indirectly, with any Person (as defined below) to distribute any of the Preferred Shares. For purposes of this Agreement, “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and any governmental entity or any department or agency thereof.

 

    - 2 - 

     

    

 

(b)
Accredited Investor Status. Such Buyer is an “accredited investor” as that term is defined in Rule 501(a) of
Regulation D.

 

(c)
Reliance on Exemptions. Such Buyer understands that the Preferred Shares are being offered and sold to it in reliance on
specific exemptions from the registration requirements of United States federal and state securities laws (including the 1933
Act) and that the Company is relying in part upon the truth and accuracy of, and such Buyer’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of such Buyer set forth herein in order to determine the availability
of such exemptions and the eligibility of such Buyer to acquire the Preferred Shares.

 

(d)
Information. Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances
and operations of the Company and materials relating to the offer and sale of the Preferred Shares, including the Bonus Agreements,
that have been requested by such Buyer. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions
of the Company. Neither such inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if
any, or its representatives shall modify, amend or affect such Buyer’s right to rely on the Company’s representations
and warranties contained herein. Such Buyer understands that its investment in the Preferred Shares involves a high degree of
risk. Such Buyer has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Preferred Shares.

 

(e)
No Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of
the investment in the Preferred Shares nor have such authorities passed upon or endorsed the merits of the offering of the Preferred
Shares.

 

(f)
Transfer or Resale. Such Buyer understands that: (i) the Preferred Shares have not been and are not being registered under
the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (x) the Company
shall have provided its written approval therefor and (y) either (A) subsequently registered thereunder, (B) such Buyer shall
have delivered to the Company an opinion of counsel, in a generally acceptable form, to the effect that such Preferred Shares
to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C)
such Buyer provides the Company with reasonable assurance that such Preferred Shares can be sold, assigned or transferred pursuant
to Rule 144 or Rule 144A promulgated under the 1933 Act, as amended, (or a successor rule thereto) (collectively, “Rule
144”); (ii) any sale of the Preferred Shares made in reliance on Rule 144 may be made only in accordance with the terms
of Rule 144 and further, if Rule 144 is not applicable, any resale of the Preferred Shares under circumstances in which the seller
(or the Person) through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may
require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii)
neither the Company nor any other Person is under any obligation to register the Preferred Shares under the 1933 Act or any state
securities laws or to comply with the terms and conditions of any exemption thereunder.

 

    - 3 - 

     

    

 

(g)
Legends. Such Buyer understands that the certificates or other instruments representing the Preferred Shares shall bear
a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock
certificates):

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED, OR ASSIGNED (I) IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION
OF COUNSEL SELECTED BY THE HOLDER, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS
SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. IN ADDITION, THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED,
PLEDGED, OR ASSIGNED UNLESS SUCH SALE, TRANSFER, PLEDGE OR ASSIGNMENT IS PERMITTED IN ACCORDANCE WITH THE AND CERTIFICATE OF DESIGNATION.

 

(h)
Validity; Enforcement. This Agreement and the other Transaction Documents to which such Buyer is a party have been duly
and validly authorized, executed and delivered on behalf of such Buyer and shall constitute the legal, valid and binding obligations
of such Buyer enforceable against such Buyer in accordance with their respective terms, except as such enforceability may be limited
by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(i)
No Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the other Transaction Documents
to which such Buyer is a party and the consummation by such Buyer of the transactions contemplated hereby and thereby will not
(i) result in a violation of the organizational documents of such Buyer, (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which such Buyer is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Buyer,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations
hereunder.

 

    - 4 - 

     

    

 

(j)
Consents. Buyer is not required to obtain any consent, authorization or order of, or make any filing or registration with
any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations under or contemplated by the Transaction Documents, in each case in accordance with the terms
hereof or thereof.

 

(k)
No Other Representations or Warranties. Except for the representations and warranties contained in this Section 2, neither
Buyer nor any other Person on behalf of Buyer makes any other express or implied representation or warranty with respect to Buyer
or with respect to any other information provided by or on behalf of Buyer.

 

3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The
Company represents and warrants to each of the Buyers that, as of the date hereof and as of the Closing Date:

 

(a)
Organization and Qualification.

 

(i)
Each of the Company and each of its “Subsidiaries” (which for purposes of this Agreement means any joint venture
or any entity in which the Company, directly or indirectly, owns more than 50% of the capital stock or equity or similar interest)
are entities duly organized and validly existing and in good standing (excluding for purposes of the representation regarding
good standing, any Subsidiary formed in Israel) under the laws of the jurisdiction in which they are formed, and have the requisite
power and authorization to own their properties and to carry on their business as now being conducted and as presently proposed
to be conducted.

 

(ii)
Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing
in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to
have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse
effect, on or affecting (A) the business, properties, assets, liabilities, operations, results of operations, or condition (financial
or otherwise) of the Company and of the Subsidiaries, taken as a whole, or (ii) on the transactions contemplated hereby or the
other Transaction Documents; provided however that “Material Adverse Effect” shall not include any event, occurrence,
fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions;
(ii) conditions generally affecting the industries in which the Company operates; (iii) any changes in financial, banking
or securities markets in general, including any disruption thereof and any decline in the price of any market index or any change
in prevailing interest rates; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation
or worsening thereof; (v) any changes in applicable laws or accounting rules following the date hereof; (vi) the public announcement
or completion of the Transactions contemplated by this Agreement (provided that no such announcement shall be in violation of
the terms hereof); (vii) any natural disaster or acts of God; (viii) any failure by the Company to meet any internal
or published projections, forecasts or revenue or earnings predictions (provided that the underlying causes of such failures (subject
to the other provisions of this definition) shall not be excluded); or (ix) any changes in the share price of the Company (provided
that the underlying causes of such changes shall not be excluded); except in the case of (i), (ii), (iii), (iv), (v) or (vii)
above to the extent these effects or changes do not have a disproportionate effect or change on the Company as compared to other
Persons in the industries in which the Company operates.

 

    - 5 - 

     

    

 

(b)
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement, the Certificate of Designations and each of the other agreements entered into by the parties
hereto in connection with the transactions contemplated by this Agreement (collectively, the “Transaction Documents”)
and to issue the Preferred Shares in accordance with the terms hereof and thereof. The execution and delivery of this Agreement
and the other Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby
and thereby, including, without limitation, the issuance of the Preferred Shares have been duly authorized by the Company’s
Board of Directors and (other than the filing with the SEC of a Form D and the 8-K Filing, the filing of the Certificate of Designations
with the Secretary of State of Delaware, and other filings as may be required by state securities agencies) no further filing,
consent, or authorization is required by the Company, its Board of Directors or its stockholders. This Agreement and the other
Transaction Documents have been duly executed and delivered by the Company, and constitute the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. On or before the
Closing, the Certificate of Designations in the form attached hereto as Exhibit A will have been filed with the Secretary
of State of the State of Delaware and be in full force and effect, enforceable against the Company in accordance with its terms
and will not have been amended.

 

(c)
Issuance of Preferred Shares. The issuance of the Preferred Shares is duly authorized and, upon issuance in accordance
with the terms of the Transaction Documents, shall be validly issued and free from all preemptive or similar rights, taxes, liens,
charges and other encumbrances with respect to the issue thereof and shall be fully paid and nonassessable with the holders being
entitled to the rights and preferences set forth in the Certificate of Designations. Assuming in part the accuracy of each of
the representations and warranties of the Buyers set forth in Section 2 of this Agreement, the offer and issuance by the Company
of the Preferred Shares is exempt from registration under the 1933 Act.

 

(d)
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Preferred
Shares) will not (i) result in a violation of the Company’s Certificate of Incorporation, as amended and as in effect on
the date hereof (the “Certificate of Incorporation”), and the Company’s Bylaws, as amended and as in
effect on the date hereof (the “Bylaws”), , any memorandum of association, certificate of incorporation, certificate
of formation, bylaws, any certificates of designations or other constituent documents of the Company or any of its Subsidiaries,
any capital stock of the Company or any of its Subsidiaries or the articles of association or bylaws of the Company or any of
its Subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of,
any material agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) to the knowledge
of the Company, result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and
state securities laws and regulations and the rules and regulations of the OTC QB (the “Principal Market”)
and applicable laws of the State of Delaware and any foreign, federal, and other state laws) applicable to the Company or any
of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.

 

    - 6 - 

     

    

 

(e)
Consents. The Company is not required to obtain any consent, authorization or order of, or make any filing or registration
with (other than the filing with the SEC of a Form D and the 8-K Filing, the filing of the Certificate of Designations with the
Secretary of State of Delaware, and other filings as may be required by state securities agencies), any court, governmental agency
or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Transaction Documents, in each case in accordance with the terms hereof or thereof. All consents,
authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have
been obtained or effected on or prior to the Closing Date (or in the case of the filings detailed above, will be made timely after
the Closing Date), and the Company and its Subsidiaries are unaware of any facts or circumstances that might prevent the Company
or any of its Subsidiaries from obtaining or effecting any of the consent, registration, application or filings pursuant to the
preceding sentence.

 

(f)
Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting
solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby and that no Buyer, other than Buyers that have indicated that they are affiliates of the Company on their signature
page, is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate” of the Company
or any of its Subsidiaries (as defined in Rule 144) or (iii) to the knowledge of the Company, a “beneficial owner”
of more than 10% of the shares of Common Stock of the Company (as defined for purposes of Rule 13d-3 of the Securities Exchange
Act of 1934, as amended (the ”1934 Act”)). The Company further acknowledges that no Buyer is acting as a financial
advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the Transaction Documents
and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents
in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such
Buyer’s purchase of the Preferred Shares. The Company further represents to each Buyer that the Company’s decision
to enter into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives.

 

(g)
No General Solicitation; Broker’s Fees. Neither the Company, nor any of its Subsidiaries or affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Preferred Shares. Except as expressly set forth herein, the Company shall be responsible
for the payment of any placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for Persons
engaged by any Buyer or its investment advisor) relating to or arising out of the transactions contemplated hereby.

 

    - 7 - 

     

    

 

(h)
No Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, and any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration
with prior offerings or otherwise, or cause this offering of the Preferred Shares to require the approval of the stockholders
of the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation,
under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are
listed or designated for quotation. None of the Company, its Subsidiaries, their affiliates or any Person acting on their behalf
will take any action or steps referred to in the preceding sentence that would require registration of the issuance of any of
the Securities under the 1933 Act or cause the offering of any of the Securities to be integrated with other offerings for purposes
of any such applicable stockholder approval provisions.

 

(i)
Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison
pill (including, without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under
the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its formation which
is or could become applicable to any Buyer as a result of the transactions contemplated by this Agreement. The Company has not
adopted a stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or
a change in control of the Company or any of its Subsidiaries.

 

(j)
SEC Documents; Financial Statements. Since January 1, 2019, the Company has timely filed all reports, schedules, forms,
statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act
(all of the foregoing filed prior to the date hereof or prior to the Closing Date, and all exhibits included therein and financial
statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “SEC
Documents”). The Company has delivered to the Buyers or their respective representatives true, correct and complete
copies of each of the SEC Documents not available on the EDGAR system, if any (excluding, however, any confidentiality treatment
requests, and any correspondence with the SEC). As of their respective filing dates, the SEC Documents complied in all material
respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the
SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. As of their respective filing dates, the financial
statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such
financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently
applied, during the periods involved (“GAAP”) (except (i) as may be otherwise indicated in such financial statements
or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be
condensed or summary statements) and fairly present in all material respects the financial position of the Company and its Subsidiaries
as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited
statements, to normal year-end audit adjustments which will not be material either individually or in the aggregate).

 

    - 8 - 

     

    

 

(k)
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required
to be paid in connection with the sale and transfer of the Preferred Shares to be sold to each Buyer hereunder will be, or will
have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

(l)
No Disqualification Events. With respect to the Preferred Shares to be offered and sold hereunder in reliance on Rule 506(b)
under the 1933 Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated
issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial
owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor
any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of
sale (each, an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent
applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Buyers a copy of any disclosures provided
thereunder.

 

(m)
Bonus Agreements. The Company has made available to the Buyers true and complete copies of the Bonus Agreements.

 

(n)
No Other Representations or Warranties. Except for the representations and warranties contained in this Section 3, neither
the Company nor any other Person on behalf of the Company or its Subsidiaries makes any other express or implied representation
or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided by or on behalf
of the Company or its Subsidiaries, including with respect to the Bonus Agreements or the Bonus Shares (as defined therein). Without
derogating from the generality of the foregoing, Buyers acknowledge that the Company (i) shall not be liable for, nor is the Company
providing any guarantee on, or making any representations or warranties with respect to, the expected value of the Bonus Shares
(including the Advance Shares) or their tradeability (including due to any limitations under applicable securities laws) and (ii)
subject to the Price Restriction (as defined below) and limitations under applicable securities laws, the Company will be able
to freely resell the Bonus Shares at any time and from time to time.

 

4.
COVENANTS.

 

(a)
Best Efforts. Each party shall use its best efforts timely to satisfy each of the covenants and the conditions to be satisfied
by it as provided in Sections 6 and 7 of this Agreement.

 

    - 9 - 

     

    

 

(b)
Form D. The Company agrees to timely file a Form D with respect to the Preferred Shares as required under Regulation D.

 

(c)
Reporting Status. From the Closing and until the date on which the Buyers no longer hold any Preferred Shares (the “Reporting
Period”), the Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and
the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the
rules and regulations thereunder would no longer require or otherwise permit such termination.

 

(d)
Use of Proceeds. The Company will use the proceeds from the sale of the Preferred Shares primarily in order to fund the
purchase of the Bonus Shares (as defined in the Bonus Purchase Agreement); it being understood that, as more fully set forth herein
and in the Escrow Agreement (A) $500,000 (the “Advance”) out of the Aggregate Purchase Price shall be released
by the Escrow Agent to Bonus (through the Bonus Escrow Agent) as soon as possible following the date hereof (i.e., before the
Closing) and the balance thereof shall be released by the Escrow Agent to the Bonus Escrow Agent at Closing; (B) upon the Closing,
(i) $3,200,000 out of the Aggregate Purchase Price shall be released by the Bonus Escrow Agent to Bonus and (ii) transaction fees
and expenses of the Company for the transactions contemplated hereunder and under the Bonus Agreements (the “Company
Expenses”) of $100,000 (the “Expenses Cap”) will be remitted to the Company; and (C) $3,700,000 out
of the Aggregate Purchase Price (the “NASDAQ Payment Amount”) shall be released by the Bonus Escrow Agent to
Bonus upon the earlier of (i) the Milestone Closing (as defined in the Bonus Purchase Agreement), or (ii) upon the written consent
of the Required Holders.

 

(e)
Bonus Shares. The Company shall have no limitation on the transfer, sale or disposition of the Bonus Shares (as defined
in the Bonus Purchase Agreement), and may transfer, sell or dispose such Bonus Shares at any time, and from time to time, in the
Company’s sole discretion. Notwithstanding the foregoing, for as long as any Preferred Shares remain outstanding, the Company
shall not sell, transfer or dispose of any Bonus Shares for a price per share equal to less than NIS 0.40 (subject to adjustments
in case of stock splits, consolidation, share dividend (including any dividend or distribution of securities convertible into
share capital), reorganization, reclassification, combination, recapitalization or other like change with respect to the Bonus
Shares), unless such sale, transfer or disposition is approved in writing by the Required Holders (the “Price Restriction”).

 

(f)
Disclosure of Transactions. On or before the Disclosure Time (as defined below), the Company
shall issue a press release and file a Current Report on Form 8-K, describing the terms of the transactions contemplated by this
Agreement in the form required by the 1934 Act and attaching this Agreement and the form of the Certificate of Designations as
exhibits to such filing (including all attachments), the “8-K Filing”). As used herein, “Disclosure
Time” means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time)
and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof, , or (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time)
on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof.

 

    - 10 - 

     

    

 

(g)
Assignment of Rights under the Bonus Purchase Agreement. Effective as of the Closing, the Company undertakes that simultaneously
with, or promptly after, the redemption of the Preferred Shares, it shall also assign the rights of the Company under the Bonus
Purchase Agreement and the Registration Rights Agreement (as defined therein) as more fully set forth in Exhibit B hereto.

 

(h)
Guarantee. It is hereby agreed that, notwithstanding anything to the contrary hereunder, including Section 1(d) hereof,
“Purchase Price”, for all intents and purposes hereunder and under the other Transaction Documents, may consist (and
therefore, the definition of such terms shall include) of an executed bank guarantee or other similar instrument; provided
that (A) Buyers may not use such instrument (in lieu of cash) unless (i) the form and substance thereof is acceptable to the
Company in its full discretion and (ii) an unexecuted copy of such instrument has been made available to the Company by such Buyer
at least 48 hours (or less, if approved in writing by the Company) prior to the execution of this Agreement, and (B) without derogating
from any of its other rights and remedies under this Agreement and by applicable law, such Buyer shall not be issued any Preferred
Shares at Closing or thereafter unless such instrument is replaced by Buyer with (or is converted by the Company, at its sole
discretion, into) freely unrestricted cash, in US dollars, by no later than 45 days (or more, if approved in writing by the Company)
following the Closing.

 

5.
REGISTER; TRANSFER AGENT INSTRUCTIONS.

 

(a)
Register. The Company shall maintain at its principal executive offices (or such other office or agency of the Company
as it may designate by notice to each holder of Preferred Shares), a register for the Preferred Shares in which the Company shall
record the name and address of the Person in whose name the Preferred Shares have been issued (including the name and address
of each transferee). The Company shall keep the register open and available at all times during business hours for inspection
of any Buyer or its legal representatives.

 

6.
CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

The
obligation of the Company hereunder to issue and sell the Preferred Shares to each Buyer at the Closing is subject to the satisfaction,
at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s
sole benefit and may be waived by the Company at any time in its sole discretion by providing each Buyer with prior written notice
thereof:

 

(i)
Such Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company.

 

(ii)
Such Buyer shall have delivered its Purchase Price to the Company (or to the Escrow Account, as applicable) for the Preferred
Shares being purchased by such Buyer on the date hereof (or such other time agreed in writing by the Company) by wire transfer
of immediately available funds pursuant to the wire instructions provided by the Company.

 

(iii)
The representations and warranties of such Buyer shall be true and correct as of the date when made and as of the Closing Date
as though made at that time (except for representations and warranties that speak as of a specific date which shall be true and
correct as of such specified date), and such Buyer shall have performed, satisfied and complied in all material respects with
the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer
at or prior to the Closing Date.

 

    - 11 - 

     

    

 

(iv)
The closing of the Bonus Purchase Agreement shall have occurred simultaneously with, or immediately after, the Closing pursuant
to this Agreement.

 

7.
CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

The
obligation of each Buyer hereunder to purchase the Preferred Shares set forth opposite such Buyer’s name in column (3) of
the Schedule of Buyers at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following
conditions, provided that these conditions may be waived in writing by the Required Holders:

 

(i)
The Company shall have duly issued and delivered to such Buyer the Preferred Shares (allocated in such amounts as such Buyer shall
request), being purchased by such Buyer at the Closing pursuant to this Agreement as set forth opposite such Buyer’s name
in column (3) of the Schedule of Buyers.

 

(ii)
The Company shall have delivered to such Buyer a certificate evidencing the formation and good standing of the Company issued
by the Secretary of State (or comparable office) of Delaware, as of a date within not more than ten (10) days prior to the Closing
Date.

 

(iii)
The representations and warranties of the Company shall be true and correct in all material respects as of the date when made
and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date which shall be true and correct as of such specified date) and the Company shall have performed, satisfied and complied in
all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied
or complied with by the Company at or prior to the Closing Date. Such Buyer shall have received a certificate, executed by the
Chief Executive Officer of the Company, dated as of the Closing Date, to the foregoing effect.

 

(iv)
The Certificate of Designations in the form attached here to as Exhibit A shall have been filed with the Secretary of State
of the State of Delaware and shall be in full force and effect, enforceable against the Company in accordance with its terms and
shall not have been amended.

 

(v)
Such Buyer shall have received the Company’s wire instructions on Company’s letterhead duly executed by an authorized
executive officer of the Company.

 

(vi)
The closing of the Bonus Purchase Agreement shall have occurred simultaneously with, or immediately after, the Closing pursuant
to this Agreement.

 

8.
TERMINATION. In the event that the Closing shall not have occurred on or before 5:00 p.m. (IL Time) on the 30th
day following the date hereof (as such time may be extended by the written consent of the Company and the Required Holders),
either party may terminate this Agreement by written notice to the other party; provided that (i) the party seeking
to terminate this Agreement pursuant to this ‎Section shall not have breached in any material respect its obligations
under this Agreement in any manner that shall have caused the failure to consummate the Closing on or before such time and (ii)
the Company undertakes that if (A) the Advance is released by the Escrow Agent to Bonus (through the Bonus Escrow Agent) and (B)
no Closing occurred, the Company shall distribute all (100%) of the Advance Shares (as defined in the Bonus Purchase Agreement),
in no event later than six (6) months thereafter, to the Buyers (on a pro rata basis amongst the Buyers based on their portion
of the Aggregate Purchase Price initially transferred to the Escrow Agent).

 

    - 12 - 

     

    

 

9.
MISCELLANEOUS.

 

(a)
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of Delaware, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the State of Delaware, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING
OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(b)
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party; provided that a facsimile or .pdf signature shall be considered due execution and shall be binding upon the signatory thereto
with the same force and effect as if the signature were an original, not a facsimile or .pdf signature.

 

(c)
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

(d)
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred
upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).

 

(e)
Entire Agreement; Amendments. This Agreement and the other Transaction Documents supersede all other prior oral or written
agreements between the Buyers, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed
herein, and this Agreement, the other Transaction Documents and the instruments referenced herein and therein contain the entire
understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein
or therein, neither the Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such
matters. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of the Company and the Required Holders; provided
that any such amendment or waiver that complies with the foregoing but that disproportionately, materially and adversely affects
the rights and/or obligations of any Buyer(s) or holder(s) of Preferred Shares relative to the comparable rights and/or obligations
of the other Buyers or holders of Preferred Shares shall require the prior written consent of such adversely affected Buyer(s)
or holder(s) of Preferred Shares. Any amendment or waiver effected in accordance with this Section 9(e) shall be binding upon
each Buyer and holder of Preferred Shares and the Company. No such amendment shall be effective to the extent that it applies
to less than all of the Buyers or holders of Preferred Shares. No consideration shall be offered or paid to any Person to amend
or consent to a waiver or modification of any provision of this Agreement unless the same consideration (other than the reimbursement
of legal fees) also is offered to all of the parties to this Agreement. The Company has not, directly or indirectly, made any
agreements with any Buyers relating to the terms or conditions of the transactions contemplated by the Transaction Documents except
as set forth in the Transaction Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this
Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any financing to the Company or
otherwise.

 

    - 13 - 

     

    

 

(f)
Notices. Any notices, consents, waivers or other communications required or permitted to be
given under the terms of this Agreement or any of the other Transaction Documents must be in writing and will be deemed to have
been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent by facsimile (provided confirmation
of transmission is mechanically or electronically generated and kept on file by the sending party); (iii) upon delivery, when
sent by electronic mail (provided that the sending party does not receive an automated rejection notice); or (iv) one Business
Day after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses,
facsimile numbers and e-mail addresses for such communications shall be:

 

	 	If to the Company:
	 	Wize Pharma, Inc.
	 	24 Hanagar Street
	 	Hod Hasharon 4527708 
	 	Israel
	 	Telephone:	972 (72) 260-0536
	 	Facsimile:	972 (72) 260-0537
	 	Attention:	Or Eisenberg
	 	E-mail:	or@wizepharma.com

 

If
to a Buyer, to its address, facsimile number and e-mail address set forth on the Schedule of Buyers, with copies to such Buyer’s
representatives as set forth on the Schedule of Buyers, or to such other address, facsimile number and/or e-mail address and/or
to the attention of such other Person as the recipient party has specified by written notice given to each other party five (5)
days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent,
waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine or e-mail
containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an
overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight
courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(g)
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns, including any purchasers of the Preferred Shares. The Company shall not assign this Agreement or any rights
or obligations hereunder without the prior written consent of the Required Holders. A Buyer shall not assign this Agreement or
any rights or obligations hereunder without the prior written consent of the Company.

 

(h)
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that
each Indemnitee shall have the right to enforce the obligations of the Company with respect to Section 9(l).

 

(i)
Survival. Unless this Agreement is terminated under Section 8, the representations and warranties of the Company and the
Buyers contained in Sections 2 and 3, and the agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Closing
and the delivery of the Preferred Shares for a period of 18 months following the Closing. Each Buyer shall be responsible only
for its own representations, warranties, agreements and covenants hereunder.

 

(j)
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

    - 14 - 

     

    

 

(k)
Indemnification. In consideration of each Buyer’s execution and delivery of this Agreement and acquiring of the Preferred
Shares hereunder, the Company shall defend, protect, indemnify and hold harmless each Buyer and each other holder of the Preferred
Shares and all of their stockholders, partners, members, officers, directors, employees and direct or indirect investors and any
of the foregoing Persons’ agents or other representatives (including, without limitation, those retained in connection with
the transactions contemplated by this Agreement) (collectively, the “Indemnitees”), as incurred, from and against
any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder
is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee (unless such action is based solely upon any conduct by such Indemnitee which is finally judicially
determined to constitute fraud, gross negligence, willful misconduct or malfeasance), as a result of, or arising out of, or relating
to (a) any misrepresentation or breach of any representation or warranty made by the Company in this Agreement or any other certificate,
instrument or document contemplated hereby, (b) any breach of any covenant, agreement or obligation of the Company contained in
this Agreement or any other certificate, instrument or document contemplated hereby or (c) any cause of action, suit or claim
brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on behalf of
the Company) and arising out of or resulting from the foregoing events described in clauses (a) and (b). To the extent that the
foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the
payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable law. The maximum indemnifiable
damages shall be the Aggregate Purchase Amount.

 

(l)
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

(m)
Remedies. Each Buyer and each holder of the Preferred Shares shall have all rights and remedies set forth in this Agreement
and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of
the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be
entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach
of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in
the event that it fails to perform, observe, or discharge any or all of its obligations under this Agreement, any remedy at law
may prove to be inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to seek temporary
and permanent injunctive relief in any such case without the necessity of proving actual damages and without posting a bond or
other security.

 

(n)
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) this Agreement, whenever any Buyer exercises a right, election, demand or option under this Agreement and the Company
does not timely perform its related obligations within the periods therein provided, then such Buyer may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole
or in part without prejudice to its future actions and rights.

 

    - 15 - 

     

    

 

(o)
Payment Set Aside. To the extent that the Company makes a payment or payments to the Buyers hereunder or pursuant to any
of the other Transaction Documents or the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or
payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal
law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.

 

(p)
Independent Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document
are several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance
of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges
that the Buyers do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a
presumption that the Buyers are in any way acting in concert or as a group, and the Company shall not assert any such claim with
respect to such obligations or the transactions contemplated by the Transaction Documents and the Company acknowledges that the
Buyers are not acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. The Company acknowledges and each Buyer confirms that it has independently participated in the negotiation of the transaction
contemplated hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents,
and it shall not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose.

 

(q)
Blue Sky Qualification. The purchase of Preferred Shares under this Agreement is expressly conditioned upon the
exemption from qualification of the offer and sale of the Preferred Shares from applicable federal and state securities laws.
The Company shall not be required to qualify this transaction under the securities laws of any jurisdiction and, should qualification
be necessary, the Company shall be released from any and all obligations to maintain its offer, and may rescind any sale contracted,
in the jurisdiction.

 

[Signature
Page Follows]

 

    - 16 - 

     

    

 

IN
WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement
to be duly executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	WIZE PHARMA, INC.
	 	 
	 	By:	    
	 	 	Name:
	 	 	Title:

 

[Signature Page
to Securities Purchase Agreement]

 

     

     

    

 

[PURCHASER
SIGNATURE PAGES TO WIZE PHARMA, INC. SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement
to be duly executed as of the date first written above.

 

Name
of Buyer: ___________ _________________________________________________

 

Signature
of Authorized Signatory of Buyer: ________________________________________

 

Name
of Authorized Signatory: _______ __________________________________________

 

Title
of Authorized Signatory: ________ __________________________________________

 

Email
Address of Authorized Signatory: ___________________________________________

 

Address
for Notice to Buyer: _________________________________________________________

 

Address
for Delivery of Stock Certificate (if not same as address for notice):

 

Affiliate
of the Issuer: ______ [Check if an affiliate of the Company]

 

Subscription
Amount: $__________________________

 

SSN/EIN:
______________________________

 

[Signature
Page to Securities Purchase Agreement]

 

     

     

    

 

SCHEDULE
OF BUYERS

 

	(1)	 	(2)	 	(3)	 	 	(4)	 	 	(5)
	 	 	 	 	 	 	 	 	 	 	 
	Buyer	 	Address, Facsimile Number and Email	 	Number of Preferred Shares	 	 	Purchase Price	 	 	Legal Representative’s Address, Facsimile Number and Email
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	[●]	 	 	$	[●]	 	 	 
	 	 	 	 	 	[●]	 	 	$	[●]	 	 	 
	 	 	 	 	 	[●]	 	 	$	[●]	 	 	 
	[Other Buyer]	 	 	 	 	[●]	 	 	$	[●]	 	 	 
	TOTAL	 	 	 	 	[●]	 	 	$	[●]Blueprint

 Exhibit
10.1

 

	

AMENDMENT 3

	

TO THE

	

COLLABORATIVE RESEARCH AGREEMENT

	

BETWEEN

	

GENERAL ELECTRIC COMPANY

	

AND

	

ENDRA LIFE SCIENCES INC.

	
 

	

This
Amendment 3 to the Collaborative Research Agreement ("Amendment"),
effective as of the last date of signing below ("Effective Date"),
amends the Collaborative Research Agreement between General
Electric ("GE") & ENDRA Life Sciences Inc. ("ENDRA"), which
became effective as of April 22, 2016, as amended by that certain
Amendment 1 to the Collaborative Research Agreement, dated April
21, 2017, and by that certain Amendment 2 to the Collaborative
Research Agreement, dated January 30, 2018
("Agreement").

	

RECITALS

	

WHEREAS,
the parties wish to amend the Agreement to provide for a revised
TERM, which includes changes to the Agreement as set forth below;
and

 

WHEREAS,
the parties wish to modify the Research Program following
ENDRA’s presentation of its Final Report with respect to the
Research Program on December 4, 2019.

	

THEREFORE,
the parties hereby agree to the following amendment:

	

1. Section 9.1
of the Agreement shall be deleted and restated as
follows:

 

This Agreement will remain in effect until January 14, 2021 unless
terminated sooner or extended in writing signed by the parties in
accordance with this Agreement.

	

2. Exhibit A
of the Agreement shall be deleted and restated with Exhibit A
attached hereto.

	

3. Capitalized
terms not defined in this Amendment will have the meanings assigned
in the Agreement.

	

4. Except as
explicitly modified, all terms, conditions and provisions of the
Agreement shall continue in full force and effect.

	

5. In the
event of any inconsistency or conflict between the Agreement and
this Amendment, the terms, conditions and provisions of this
Amendment shall govern and control.

	

6. This
Amendment and the Agreement constitute the entire and exclusive
agreement between the parties with respect to this subject matter.
All previous discussions and agreements with respect to this
subject matter are superseded by the Agreement and this
Amendment.

 

 

Signature Page Follows

 

 

1

 

 

Acceptance
of these terms is documented by the signature and date of the
responsible parties in the space designated below.

 

	

GE Healthcare

 

	
 

	

ENDRA Life Sciences Inc.

 

	

Signature:

	

/s/
Brian McEathron

	
 

	

Signature:

	

/s/
Francois Michelon

	

Name:

	

Brian
McEathron

	
 

	

Name:

	

Francois
Michelon

	

Title:

	

GM
General Imaging Ultrasound

	
 

	

Title:

	

CEO

	

Date:

	

January
13, 2020

	
 

	

Date:

	

January
13, 2020

 

Signature Page to Amendment No 3 to Collaborative Research
Agreement 

 

 

2

 

 

EXHIBIT A:

 

RESEARCH PROGRAM COMPONENTS

 

ENDRA
wishes to commercialize its Thermo-Acoustic Enhanced UltraSound
(TAEUSTM) technology, and GE wishes to assist ENDRA in this
goal.

 

To this
end, GE agrees to provide ENDRA with the following:

 

1.      
 The Consignment of a cart-based GE ultrasound system, of
GE’s choosing, which ENDRA can use to develop an interface
for its TAEUS technology. The GE equipment will at all times remain
the property of GE. ENDRA may access the internal hardware and
software components of GE’s ultrasound system to develop the
TAEUS interface. ENDRA may request drawings or information from GE
to achieve a successful interface, which GE may provide under
confidentiality and the terms of this Agreement at its sole
discretion. ENDRA will take reasonable measures to protect the GE
system from damage or theft, as it would for an ENDRA-owned piece
of capital equipment.

 

2. 

GE
will provide (within its sole discretion) ad-hoc engineering
support to assist ENDRA with the development of the TAEUS
interface, and to help avoid damage to the GE ultrasound
system.

 

3. 

GE will provide (within its sole discretion)
ad-hoc commercial advice to assist ENDRA with the development of a
TAEUSTM commercialization plan.

 

4. 

GE
will facilitate (within its sole discretion) introductions for
ENDRA to GE clinical ultrasound customers, as potential beta-users
and clinical advisors for ENDRA’s TAEUS technology. GE cannot
guarantee these introductions will lead to formal customer
collaborations.

 

In return for GE’s assistance with development of the
TAEUSTM technology, ENDRA
agrees to the following:

 

1. 

ENDRA
will keep GE informed of progress it makes in developing a TAEUS-GE
product interface, and any contact or collaboration ENDRA
undertakes with GE-introduced clinical customers. ENDRA will
participate in regular update telephone calls with designated GE
representatives.

 

2. 

Prior
to ENDRA commercially releasing (directly or indirectly) the TAEUS
technology for a Fatty Liver Application (“FLA”), ENDRA
will offer to negotiate in good faith an exclusive ultrasound
manufacturer relationship with GE for a period of at least one (1)
year of commercial sales (“Sales Option”). The
commercial sales will involve, within ENDRA’s sole
discretion, either (1) ENDRA commercially selling GE Healthcare
ultrasound systems as the exclusive ultrasound system with their
TAEUS FLA embedded, or (2) GE Healthcare being the exclusive
ultrasound manufacturer to sell ultrasound systems with the TAEUS
FLA technology embedded. Notwithstanding the foregoing, the Sales
Option will in no way prevent ENDRA from selling its TAEUS FLA
technology to distributors or directly to non-manufacturer
purchasers.

 

3. 

In
addition, prior to ENDRA offering to license any of the TAEUS FLA
IP to a third party, ENDRA will first offer to negotiate in good
faith to license such TAEUS FLA IP to GE (“License
Option”).

 

4. 

Moreover,
prior to ENDRA offering to sell any equity interests to a
healthcare device manufacturer, ENDRA will first offer to negotiate
in good faith to sell such equity interests to GE (“Equity
Option”).

 

5. 

The
Sales Option, License Option and Equity Option (each, an
“Option” and, collectively, the “Options”)
shall each start as of the Effective Date and each automatically
terminate after the earlier of (i) thirty (30) days following
ENDRA’s offering to negotiate with GE with respect to such
Option and (ii) ninety (90) days after the termination or
expiration of the Agreement (“Option
Period”).

 

6. 

GE may exercise any of its Options by providing
written notice to ENDRA prior to the expiration of the Option
Period. Upon exercise of the Option and for a period of three (3)
months thereafter, or in the case of the Equity Option, for a
period of one (1) month thereafter (the “Negotiation
Period”), ENDRA and GE agree to negotiate in good faith to
draft and execute a written agreement consistent with GE’s
Option selection. Notwithstanding the foregoing, ENDRA shall not be
prevented during the Negotiation Period from negotiating with third
parties the subject of any Option. If the Parties are unable to
agree on mutually acceptable terms and conditions for such an
agreement within the Negotiation Period, then ENDRA agrees for a
period of one (1) year thereafter (the “Tail Period”)
not to enter into a similar agreement with a third party on terms
and conditions that are materially better for the third party in
any respect than, or substantially equal for the
third party with respect to, the
comparable terms and conditions last proposed by GE without first
offering such materially better or substantially equal terms and
conditions to GE. If at any time during the Negotiation Period or
the Tail Period ENDRA submits to GE terms proposed by a third party
for a transaction that would be subject to an Option (the
“Third Party Terms”), GE shall have twenty (20) days
from such submission to notify ENDRA in writing that it elects to
contract with ENDRA on the Third Party Terms, in which case GE and
ENDRA shall thereafter enter into a contract reflecting such Third
Party Terms as promptly as practicable. If GE does not notify ENDRA
of such election in such 20-day period, ENDRA shall have satisfied
its obligations to GE with respect to the applicable Option and be
entitled to contract with a third party on terms substantially
similar to those submitted to GE.

 

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]